MARKETS / NASDAQ / BCPC

NASDAQ · CHEMICALS & ALLIED PRODUCTS · LARGE CAP

Balchem Corp. BCPC

17 fiscal years on record · USD · FY2025 reported · SEC filings only

3 YEARS OF DIVIDEND GROWTH

Revenue

$1.0B

▲ 8.8% YoY

Net income

$154.8M

▲ 20.5% YoY

In brief

What this company does

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. As of December 31, 2025, it employed approximately 1,352 full-time employees worldwide, of whom approximately 16% were covered by collective-bargaining agreements. It holds over 130 patents and over 400 registered trademarks in the United States and overseas. Its three reportable segments are Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition and Health segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition and Health segment provides nutritional products derived from microencapsulation and chelation technologies, in addition to the essential nutrient choline chloride. The Specialty Products segment re-packages and distributes performance gases and chemicals, notably ethylene oxide, propylene oxide and ammonia, for various customer uses. Balchem Corporation was incorporated in the State of Maryland in 1967.

Written from the business description in Balchem Corporation's annual report to the U.S. Securities and Exchange Commission, filed 20 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.0B

Revenue, FY2025 · full 17-year series below

Revenue $B Net income $B

FY2025 · Revenue 1.0 · Net income 0.2

Compound annual growth

Revenue

+3.2%

+8.1%

+6.5%

+9.8%

Net income

+13.7%

+12.8%

+10.0%

+10.8%

EPS, diluted

+13.5%

+12.8%

+9.7%

+10.1%

Dividend / share

+10.6%

Returned to shareholders

+33.7%

+49.9%

+29.9%

+28.1%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +8.1% a year over five years — but profit grew faster: net income at +12.8%, earnings per share at +12.8%.

The share count fell from 0.03B to 0.03B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

15 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 20.2% · Net 14.9%

ROE

FY2025 · ROE 12.9%

Gross margin35.7%

Operating margin20.2%

Net margin14.9%

Return on assets9.5%

EBITDAUSD 255.0M

Each USD of equity produced 13 cents of profit this year.

Cash & shareholders

USD 126.6M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2022 · FCF 89.5

Net buybacks $M Dividends $M

FY2025 · Dividends 28.3 · Net buybacks 98.3

Dividends paidUSD 28.3M

Net buybacksUSD 98.3M

Share of profit81.8%

Consecutive raises3 years

USD 28.3M in dividends and USD 98.3M in buybacks — 82% of the year's profit went back to shareholders.

Total assetsUSD 1.7B

EquityUSD 1.3B

CashUSD 74.6M

Current ratio2.07×

Equity funds 75% of total assets.

The 17-year record

17 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue $B	1.0	1.0	0.9	0.9	0.8	0.7	0.6	0.6	0.6	0.6	0.6	0.5	0.3	0.3	0.3	0.3	0.2
Operating income $B	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0
EBITDA $B	0.3	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
Income tax $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income $B	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0
Free cash flow $B	·	·	·	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0
EPS, diluted $	4.75	3.93	3.35	3.25	2.94	2.60	2.45	2.42	2.79	1.75	1.89	1.69	1.45	1.32	1.28	1.12	0.93
Dividend / sh $	0.96	0.87	0.79	0.71	·	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	18	20	21	20	19	20	19	17	13	19	15	15	0	29	11	9	7
ROE %	12.9	11.7	10.9	11.6	11.3	10.8	11.1	12.0	15.8	11.4	14.0	14.6	14.8	15.8	18.5	17.8	·
Shares out B	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 84 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 11 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityChemicals & Allied Products

Listed onNASDAQ

Incorporated inMaryland

Fiscal year endsDecember 31

Data on record since2008